Clearmind Medicine新药CMND-100在FDA批准的酒瘾临床试验中达成主要终点

美股速递
Apr 14

Clearmind Medicine Inc.(简称:Clearmind Medicine)旗下创新药物CMND-100,在获得美国食品药品监督管理局(FDA)批准的I/IIa期临床试验中,成功达成针对酒精使用障碍(即酒瘾)治疗的主要研究终点。该试验旨在评估CMND-100在酒瘾患者中的安全性和初步疗效,此次达成主要终点标志着其在临床开发进程中取得重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10